Dana M Blumberg1, Reena Vaswani1, Eva Nong2, Lama Al-Aswad1, George A Cioffi1. 1. Department of Ophthalmology, Harkness Eye Institute, Columbia University, New York, New York, United States. 2. Columbia University College of Physicians and Surgeons, New York, New York, United States.
Abstract
PURPOSE: To assess the impact on visual function of community glaucoma screening in an African American population using spectral-domain optical coherence tomography (SD-OCT). METHODS: Using a Monte Carlo microsimulation model with a 10-year time horizon, we analyzed the efficacy of SD-OCT screening on visual field outcomes in a population of African Americans who are not otherwise seeking office-based care. Outcomes included classification of visual field severity, quality-adjusted life years, and direct health care costs. RESULTS: Assuming a 60% follow-up rate, screening decreased the prevalence of undiagnosed glaucoma from 75% to 38%, and decreased the prevalence of severe visual field loss in patients with glaucoma from 29.1% to 23.9%. Conversely, screening increased the prevalence of mild visual field loss in patients with glaucoma from 9.2% to 18.7%. From initial screening through confirmatory eye examination, the screening program ("screen only") cost $98 per screened individual, and $2561 per new diagnosis of glaucoma. When considering the costs of initial screening though the resultant treatment, the screening program ("screen and treat") had an average annual cost of $79 and $2138, respectively, over a 10-year time period. The cost of one quality-adjusted life year (QALY) gained by screening, including management and treatment, in comparison with opportunistic case finding, ranged from $46,416 to $67,813. CONCLUSIONS: Our findings suggest that community SD-OCT screening in an African American population will minimize glaucoma-related visual morbidity. Ideally, strategies to maximize treatment efficacy through improved medication adherence and improved compliance with follow-up should be identified and implemented before instituting a screening program. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: To assess the impact on visual function of community glaucoma screening in an African American population using spectral-domain optical coherence tomography (SD-OCT). METHODS: Using a Monte Carlo microsimulation model with a 10-year time horizon, we analyzed the efficacy of SD-OCT screening on visual field outcomes in a population of African Americans who are not otherwise seeking office-based care. Outcomes included classification of visual field severity, quality-adjusted life years, and direct health care costs. RESULTS: Assuming a 60% follow-up rate, screening decreased the prevalence of undiagnosed glaucoma from 75% to 38%, and decreased the prevalence of severe visual field loss in patients with glaucoma from 29.1% to 23.9%. Conversely, screening increased the prevalence of mild visual field loss in patients with glaucoma from 9.2% to 18.7%. From initial screening through confirmatory eye examination, the screening program ("screen only") cost $98 per screened individual, and $2561 per new diagnosis of glaucoma. When considering the costs of initial screening though the resultant treatment, the screening program ("screen and treat") had an average annual cost of $79 and $2138, respectively, over a 10-year time period. The cost of one quality-adjusted life year (QALY) gained by screening, including management and treatment, in comparison with opportunistic case finding, ranged from $46,416 to $67,813. CONCLUSIONS: Our findings suggest that community SD-OCT screening in an African American population will minimize glaucoma-related visual morbidity. Ideally, strategies to maximize treatment efficacy through improved medication adherence and improved compliance with follow-up should be identified and implemented before instituting a screening program. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Michael A Kass; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Mae O Gordon Journal: Arch Ophthalmol Date: 2002-06
Authors: M Roy Wilson; Omofolasade Kosoko; Claude L Cowan; Pamela A Sample; Chris A Johnson; Gleb Haynatzki; Cheryl Enger; David Crandall Journal: Am J Ophthalmol Date: 2002-09 Impact factor: 5.258
Authors: Rohit Varma; Mei Ying-Lai; Brian A Francis; Betsy Bao-Thu Nguyen; Jennifer Deneen; M Roy Wilson; Stanley P Azen Journal: Ophthalmology Date: 2004-08 Impact factor: 12.079
Authors: Paula A Alhadeff; Carlos G De Moraes; Monica Chen; Ali S Raza; Robert Ritch; Donald C Hood Journal: J Glaucoma Date: 2017-05 Impact factor: 2.503
Authors: Yong Ju Song; Yong Woo Kim; Ki Ho Park; Young Kook Kim; Hyuk Jin Choi; Jin Wook Jeoung Journal: PLoS One Date: 2019-01-10 Impact factor: 3.240
Authors: An Ran Ran; Clement C Tham; Poemen P Chan; Ching-Yu Cheng; Yih-Chung Tham; Tyler Hyungtaek Rim; Carol Y Cheung Journal: Eye (Lond) Date: 2020-10-07 Impact factor: 3.775
Authors: Laura A Edwards; Deanna J Taylor; Peter Campbell; Rakhee Shah; David F Edgar; David P Crabb Journal: BMJ Open Date: 2019-11-19 Impact factor: 2.692